United States

CSL Biotherapies Announces Influenza Vaccine Pre-Booking Open for the 2009-2010 Flu Season

Largest maker of thimerosal-free flu vaccines to offer value programs for early booking

King of Prussia, PA — 12/22/2008

CSL Biotherapies, a subsidiary of one of the world’s leading manufacturers of influenza vaccine, today announced that healthcare providers now have the opportunity to pre-book the company’s influenza virus vaccine through either www.mercuryfreefluvaccine.com or the toll-free number, 1-888-435-8633. The majority of CSL Biotherapies’ vaccine supply for the 2009-2010 flu season will be offered as thimerosal-free, single-dose, pre-filled syringes. To help increase access to the thimerosal-free vaccine, CSL Biotherapies will offer value programs for a limited time to healthcare providers who pre-book through authorized distributors.

CSL Biotherapies’ value programs include favorable pricing on influenza vaccine and the RALLY™ program, which will allow healthcare providers to redeem the value of unused doses purchased for the 2009-2010 season for a certificate redeemable for CSL Biotherapies’ influenza vaccine for the 2010-2011 season. The RALLY™ program applies only to doses acquired for the 2009-2010 season and delivered after September 30, 2009.

"CSL Biotherapies is committed to meeting the growing demand for thimerosal-free influenza vaccine in several significant ways," said Robert Lefebvre, vice president/general manager of CSL Biotherapies U.S. "First, we are delivering one of the largest supplies of thimerosal-free influenza vaccine for adults to the U.S. market; second, we aim to increase early access to our thimerosal-free vaccine through a broad network of distributors and the attractive early booking pricing offer; third, we have created the RALLY™ program which gives healthcare providers the opportunity to redeem the value of unused 2009-2010 vaccine, delivered after September 30, 2009, for 2010-2011 supply. We encourage healthcare providers who wish to take advantage of these value offers to pre-book their 2009-2010 thimerosal-free vaccine as soon as possible to obtain the early booking pricing benefit and enroll in the RALLY™ program to protect their vaccine investment."

About CSL Biotherapies
The U.S. headquarters of CSL Biotherapies are located in King of Prussia, Pa. Its parent company, CSL Limited, in Melbourne, Australia, operates one of the world's largest thimerosal-free influenza vaccine facilities for global markets. CSL Biotherapies, which shares its U.S. headquarters with its sister company, CSL Behring, is commercializing influenza vaccine products globally.

Last year, CSL Limited, parent company to CSL Biotherapies, announced a $60 million (U.S.D.) investment in plant and equipment to double the manufacturing capacity of the company’s Melbourne facility to 40 million doses per season, making it one of the largest vaccine manufacturing plants in the world. Recently, CSL also completed its fill and finish facility in Kankakee, Illinois, to help accelerate delivery of flu vaccine to U.S. customers.

At CSL Biotherapies, delivering vaccines is our mission, protecting lives our passion. The CSL Group, which also includes CSL Research & Development, CSL Bioplasma, and CSL Behring, has more than 9,000 employees and operates in 27 countries worldwide. For more information, visit us at www.cslbiotherapies-us.com, or call 1-888-435-8633.

Media Contacts:
Sheila A. Burke
Director, Public Relations & Communications
Worldwide Commercial Operations
CSL Biotherapies

Abenaa (Abby) Hayes
Weber Shandwick
The information presented on this site is intended for US residents only.
© 2019 Seqirus All rights reserved.
Seqirus is a trademark of CSL Limited.

BCSL14-02-0003 06/2014